Jennifer Amador
 is a postdoctoral scholar at Oregon State Univeristy, working with Dr. Doug Keszler in the Department of Chemistry to investigate indium-free alternatives for use in transparent conducting oxide (TCO) thin films. Jenn is a facilitator for the ecosVC Lens of the Market Stage I+, and is presently working with her PI to spin out a company based on her current research. 

Jenn received her BS in chemistry from the University of Utah in 2011, and completed her PhD at OSU in 2017.

Tom Barrett, MD, MCR, is a Hospitalist physician and entrepreneur, currently President of Sympano, a diagnostic biotech startup company, with over 20 years of clinical experience and over 10 years of collaboration with engineers. The application of technology to improve patients’ lives is Tom’s passion.  Tom is a charter member of the Society of Hospital Medicine (SHM), founded the Oregon Chapter of SHM, and was active at the national level with SHM for many years.  Tom also teaches life science entrepreneurship with an Oregon Health & Science University medical student elective, and an internship program for PhDs and post docs at the Oregon Bioscience Incubator.  Tom recently started the Portland Chapter of the Society of Physician Entrepreneurs (SoPE) to connect all clinicians – those that care for patients to technology people to help patients.


Anna Brown
, PhD, is a chemical and materials entrepreneur based in Portland, OR. She completed her graduate work at Portland State University, and postdoctoral research at the OSU/OHSU College of Pharmacy. After graduate school she co-founded an advanced medical materials company, Hawthorne Materials. She is currently in the process of building her next venture, Sitka Labs. 


Rich Carter (CEO & co-founder, Valliscor) earned his B.S. degree in Chemistry from Gettysburg College in 1993 and his Ph.D. degree in Organic Chemistry from the University of Texas at Austin. Rich has authored of over 100 publications and multiple patents including technology licensed by Valliscor on proline sulfonamides and their use in asymmetric carbon-carbon bond forming transformations. Rich's expertise are in multi-step organic synthesis and reaction development. Rich is a graduate of the Oregon State University (OSU) Advantage Accelerator program and 2014 OSU Advantage Accelerator Entrepreneur of the Year. In 2015, Rich and co-founder Mike Standen were recognized as the 2015 Entrepreneurs of the Year by the Corvallis Chamber of Commerce.  In addition to his CEO role for Valliscor, Rich also is Professor and Chair of Chemistry at Oregon State University.

Travis Cook is a cross-functional business development professional with experience in managing, negotiating, and closing early-, late-, and commercial-stage definitive agreements. He is a co-inventor on 7 patent applications and is a co-author of several peer-reviewed publications, including a case study in the management textbook, Building a Case for Biotechnology. Travis is currently a Senior Technology Development Manager in TTBD at OHSU with an acute interest in startup formation. He has previously held  appointments at Galena Biopharma, Inc. (Nasdaq: GALE), Kalypsys, Inc., Ansata Therapeutics, Inc., and Mixture Sciences, Inc. Travis received a M.S. in chemistry from UC San Diego, a M.B.A. from Willamette University, and is a Certified Licensing Professional.

Rachel Dreilinger is a biomedical engineer with 19 years of experience in engineering product development, consulting, startups, lab automation, robotics, DNA synthesis, and medical and surgical device development. She is currently Co-Founder and CEO of a neurosurgery device company, NeuraMedica Inc. managing all aspects of commercialization including business development, fundraising, IP, operations, engineering development, market research and sales & marketing. She has also run a successful engineering consultancy, Radical R&D, since 2008 specializing in medical device design for clients such as OHSU, Bayer Healthcare, Ziba Design, and Acute Innovations (a subsidiary of Acumed). She has extensive experience in orthopedics, neurosurgery, dentistry, bioabsorbable polymers, mechanical design and all phases of product development. She received her B.S. degree in Bioengineering from the University of California, San Diego (UCSD) in 1999.

David H. Farrell
, PhD, FAHA, is Founder and Chief Scientific Officer of Gamma Therapeutics, Inc., an Oregon-based early stage biotechnology company developing a novel class of biopharmaceutical and diagnostic test solutions for the cardiovascular disease industry.  He is also a Professor of Surgery at the Oregon Health & Science University, and has appointments in the Department of Molecular and Medical Genetics and the Department of Physiology and Pharmacology.  His academic research interests are in the biochemistry, genetics, regulation, and epidemiology of the blood clotting factor fibrinogen.  Prof. Farrell is currently Chair of the Thrombosis 2 Committee of the American Heart Association and on the Editorial Board of the open access journal Thrombosis.  He has received SBIR/STTR grants from NIH and NSF, as well as a grant from the Office of Naval Research.

Dana Garves is the founder of Oregon BrewLab, a laboratory facility that provides an affordable, fast, and federally accredited testing service available to the fermentation industry. BrewLab offers precise and accurate analysis of beer, cider, wine, and mead to homebrewers, startups, and established facilities, regardless of size or budget. While running Ninkasi Brewing Company’s laboratory and sensory program, Ms. Garves joined Civilians for Space Exploration Team and helped design a rocket payload to launch brewer’s yeast, successfully, into space. She is active in outreach, holds QA/QC panels for the brewing community, and even created a beer science demo for OMSI (Oregon Museum of Science and Industry). She received her BS in Chemistry from the University of Oregon where she also received her love of craft beer.

Linda Hansen
 is Director of Technology Transfer for Providence Health & Services, where she works to accelerate the adoption of innovations of Providence researchers and clinicians by industry and the broader public.  She started her career at the bench with research positions in academia and early stage biotechnology companies, including Hybritech and Genetics Institute.  She transitioned into business development through consulting work. She worked at UO’s Technology Transfer office for 10 years before joining Providence in 2015. Linda received her Ph.D. in Molecular Pharmacology from Stanford University.

Rita Hansen
is the CEO of Onboard Dynamics, a company that seeks to lower fuel costs and carbon emissions by removing infrastructure barriers to driving natural gas vehicles. Their first commercial product – GoFlo™ - is an affordable, portable, and scalable refueling solution that can tap into the existing low-pressure natural gas grid or a renewable source. Rita has over 30 years of executive management, engineering and operations management, and project management experience in a diverse range of industries. Since 2006, she has specialized in early phase environments which focus on global opportunities in the alternative energy and renewables arena.

Charlotte Hodde
understands her clients’ motivations and advances their priorities tenaciously. Before joining Barran Liebman, Charlotte worked for multiple judges in the United States District Court both in California and Oregon—most recently as a law clerk to the Honorable Janice M. Stewart and the Honorable Youlee Yim You. Having trained to analyze complex cases, she now studies client stories to create the narrative that is key to a winning legal strategy. Charlotte’s practice includes working closely with employers to develop workplace policies, provide proactive advice and counsel, and defend clients under a broad range of local, Oregon, California, and federal employment laws. She holds a J.D. from the University of Oregon School of Law is a graduate of Hamilton College. 

David Knaus 
is the Founder of Apical Crop Science LLC, a Portland Oregon area Ag-tech company that leverages modern laboratory analytics, online data science and complex organic crop inputs to provide growers with the tools they need to grow extremely healthy, optimal yielding crops organically with minimal pest problems.  David is a certified International Crop Advisor with over 15 years of experience in Plant and Soil Science, Organic Crop Management and College-Level instruction in Sustainable Agriculture.  After balancing his time consulting and teaching for 7 years, he launched Apical Crop Science in 2016 as a way to apply cutting edge techniques in plant and soil science to solve real world agricultural problems.   ACS works with growers in the US and abroad on complex agriculture problems and is launching an online agriculture research platform in 2018.

Juanita Kurtin is a Director of Materials Research for OSRAM Opto Semiconductors, located in Portland, Oregon, where she works on nanomaterials for solid state lighting and related applications.  Prior to OSRAM, Juanita was the CTO and co-founder of Pacific Light Technologies, a start-up company delivering high quality nanomaterials to LED manufacturers in order to increase LED brightness and color quality. She has a background in the research of nanomaterials for various device applications, including transistors, solar cells, and light emitting diodes.

Dr. Kurtin obtained her BS degree in Chemistry from the Massachusetts Institute of Technology, and her PhD in Physical Chemistry from the University of California at Berkeley, studying with quantum dot pioneer Dr. Paul Alivisatos.


Mark Lieberman
 is Chief Startup Officer at OSU and Director of the OSU Advantage Accelerator. Previously, he served as Executive Director of the Business Technology Center of Los Angeles County (BTC), one of the largest technology incubators in the United States. Mark is a founder of Los Angeles County Technology Week, a prestigious series of events celebrating and promoting innovation and disruptive entrepreneurship in Los Angeles County. Mark has also been a successful business consultant, international banker and investment banker. He has developed and taught entrepreneurship courses at the University of Southern California, Antioch University, Cal State Los Angeles and Vatel Los Angeles. He is responsible for the success of more than 150 new and emerging companies. THE Magazine named Mark one of the 50 most Innovative Men for 2012. Mark has consulted with governments and published in the fields of entrepreneurship, incubation, angel and venture capital. He has served on many Boards, as well as on President Obama’s Rank Review Committee for 2010. Mark received his M.B.A. and Ed.D. in Organization Change from Pepperdine University.

Deron Neukomm has been working in the food and fine chemicals industries since 1995.  He has worked in variety of roles including Quality Assurance, Quality Control, and Environmental/Health/Safety/Security, and is currently the Quality Assurance Manager at W.R.Grace in Albany, Oregon.  W.R.Grace-Albany manufactures ingredients for pharmaceutical and food/dietary supplement applications under ISO9001 and GMP standards.  Deron has a MS in Quality Assurance (from California State University - Dominguez Hills) and a BS in Ag Sciences Business Management with focus minors in chemistry and food technology science (from Oregon State University).  He is an ASQ Certified Manager of Quality/Organizational Excellence and Certified Quality Auditor.

Bill Newman
is managing director at Northwest Technology Ventures, an Oregon seed fund focused on technology-based startups and spinouts from the research sector in both life sciences and technology, and Entrepreneur-in-Residence at the OTRADI Bioscience Incubator.  NTV’s seed funding has provided the leverage for the companies in NTV’s investment portfolio to raise a cumulative investment of over $200 million to date, advancing businesses through growth stages into manufacturing, sales, and profitability.  Prior to NTV Bill
spent over a decade as a scientist at the Massachusetts Institute of Technology where he directed a joint program with the Harvard Medical School in biomedical research.  He left MIT to found a start-up based this work, and subsequently entered the venture industry to focus on early-stage investments.  As EIR at OBI, he brings both the investor’s and entrepreneur’s perspective to advise entrepreneurs and early-stage businesses on business and funding strategy.  He has served on numerous corporate boards within the NTV portfolio, as well as on various academic and civic boards including past chair of the Oregon Bioscience Association and as a founding member of Oregon's Innovation Council, the state’s advisory board on knowledge and innovation based economic development. 

As a Senior Regulatory Consultant at Vision28, Michael Nilo brings a wealth of knowledge, experience and regulatory networking. In his six years with FDA, Michael has reviewed well over 100 medical device pre-market submissions (IDE, 510(k), PMA, DeNovo and HDE) to determine if devices were safe and effective. A few of the pre-market submissions Michael has reviewed include drug eluting stents, atherectomy systems, percutaneous transluminal coronary angioplasty balloons, guide catheters, embolectomy, dental implants, abutments, bone-grafting materials, bone plates, and trans-mandibular joint implants. He has an excellent grasp of what FDA reviewers are looking for in all submissions. In private industry, he has developed successful regulatory strategies and authored/submitted pre-IDE, 510(k), HDE, IDE and original PMA submissions to FDA for cardiovascular device systems and combination products (e.g., drug eluting stents and absorbable scaffolds).

Michael has a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham, and graduated from the University of Pittsburgh, with a Bachelor of Science in Bioengineering and Chemistry.


Josh Pan joined the M3 Biotechnology team in October 2015 but has been following technical and company progress since 2013 while serving as an Associate with the W Fund, a local Washington venture fund. He brings to the team a blend of technical expertise in molecular, cellular and behavioral neuroscience and business acumen.

Previous to M3 Biotechnology, he held multiple positions at the University of Washington Center for Commercialization. Josh is also Founder and Principal of S-Phase Ventures, where he provides consulting services to startup companies, venture capital firms, and non-profit organizations.

Josh earned his BS in chemistry (summa cum laude) from Oregon State University, his doctorate in 2012 through the University of Washington Molecular and Cellular Biology program and MBA in 2011 through the UW-Bothell Leadership MBA program.

Ethan PerlsjIH6GqRB.jpegtein, founder of Perlara PBC, San Francisco, CA, a biotech startup focused on precision orphan drug discovery. Dr. Perlstein received his Ph.D. in molecular and cell biology from Harvard University, and was a Lewis-Sigler Fellow at Princeton University. He is an author on 19 peer-reviewed scholarly publications, including the discovery of a novel mechanism of action for the antidepressant Zoloft based on studies in yeast cells.



Sheila Ramerman, RAC, is the founder and Principal Consultant at SJR Associates, a medical device regulatory affairs and quality systems consulting firm. SJR Associates has particular expertise with near-patient testing technologies and with assisting start-up stage companies implement their regulatory, quality, and clinical studies functions. Prior to founding SJR Associates, Ms. Ramerman was responsible for regulatory affairs, quality systems, and/or clinical studies at medical device companies in the San Francisco Bay Area. She has hands-on experience with devices in neurology, clinical laboratory, rehabilitation, orthopedics, and general hospital disciplines. She works with a wide range of medical device companies, from start-ups to multi-national corporations. She has successfully submitted over 40 510(k) submissions, and was instrumental in achieving PMA approval for a novel radiology software product. She has also been instrumental in recent de novo submissions for clients, two of which have been granted. Ms. Ramerman has been RAC certified since 1998.

Prior to her experience in the medical device industry, Ms. Ramerman was a Clinical Laboratory Scientist at community hospital laboratories in Washington State. She holds an AA in Medical Laboratory Technology from Shoreline Community College in Seattle, WA and a BA in Healthcare Administration from St. Mary’s College in Moraga, CA.


Skip Rung
 is the President and Executive Director of the Oregon Nanoscience and Microtechnologies Institute. Prior to founding ONAMI in 2003, Skip established an innovation consulting practice in 2001. He was the director of Research and Development at Hewlett-Packard’s (HP) Corvallis facility, which is both the headquarters for HP’s world-leading thermal inkjet printing technology and the company’s most advanced technology R&D and manufacturing site.
Skip has a Bachelor of Science and a Master’s degree in electrical engineering from Stanford University.

August Sick operates a private consulting practice focused on start-up to mid-stage biotechnology companies that have a need for experienced operations management, strategic planning and deal expertise; providing advisory and coaching services for founders, executives and leadership teams. In this capacity he works part time as an Entrepreneur-In-Residence for ONAMI. August brings 30 years of successful executive, entrepreneurial and investment experience. He is a co-founder and managing director of Cascade Prodrug, Inc. a development stage company engaged in anti-cancer therapeutics, and also serves as a director of Active Motif, Inc., Yecuris Corporation and Tonbo Biosciences. Previously, August was a co-founder and CEO of SupraSensor Enterprises. He was also a senior executive for Invitrogen Corporation, a career that started in 1990 as the 20th employee and covered more than 18 years. August has been instrumental in the acquisition of 18 companies and was responsible for over 100 licensing deals. He is the key inventor on 35 issued US Patents. August received a B.A. in Biochemistry and Cell Biology from the University of California San Diego.

Andy Soria is t
he Director of the Berglund Center at Pacific University, an innovation center and small business incubator established in 2014. He has been involved in the development of new products and alternative technologies in energy and materials for over 20 years. He has served at the National Academy of Science–National Research Council as an expert in biofuels, and has worked as a consultant for the International Finance Corporation (The World Bank) and Fortune 500 energy companies. Dr. Soria teaches courses in the broad context of energy, sustainability, environmental science and technology and innovation, and conducts active research in thermochemical conversion of wastes into value added products funded by NSF, USDA and other Federal Agencies.

Prior to academia, he was involved in large-scale geothermal energy, hydropower and oil and gas development across Latin America. Dr. Soria has a Ph.D. in Natural Resources-Wood Chemistry from the University of Idaho.

Joseph Steig divides his time between work as a CFO for investors and entrepreneurs and as a developer and facilitator of entrepreneurship programs and courses. He
has worked in a diverse range of industries and has extensive experience supporting universities and innovators to identify commercial opportunities for emerging technologies. With ecosVC he is currently supporting the development of a unique set of courses and programs for science innovators.

Joseph serves as Chair of Greentown Learn, the educational non-profit affiliated with the world’s largest cleantech incubator, Greentown Labs. He is also consulting CFO at Long River Ventures, a seed and early stage venture fund. Long River is actively investing out of its third fund in New England and the northeastern United States with a sector focus on healthcare technology.


Joseph grew up in Vancouver, Canada and went to Hampshire College in Amherst, Massachusetts.  More information at www.steig.com or contact joseph@steig.com.


Emily Stump has over 11 years of experience in the areas of qualification and validation, quality control testing, aseptic manufacturing, quality risk management, and creation and implementation of quality systems for biopharmaceutical products and active pharmaceutical ingredients. She holds a BS in Microbiology and a MS in Bioengineering from Colorado State University. Ms. Stump has expertise in creating and implementing quality systems and quality risk management programs, including risk-based validation programs. She has served as the lead project and qualification manager for new equipment and computer system introductions or upgrades, retrospective qualification efforts, and new or expanding facility projects. Additionally, Ms. Stump has lead multidisciplinary teams in implementing new and revised quality system and validation programs. Additionally, she has served in leadership roles for various Oregon Bioscience Association committees and is a current Board Member.


Jon Summers is an attorney and CPA who represents technology and emerging growth companies with respect to the formation, financing, governance, and transactional matters. He counsels clients on venture capital and angel financings, mergers and acquisitions, strategic alliances and joint ventures, technology licensing, commercial agreements and general business matters. Jon is experienced in stock option plans, executive compensation, corporate reorganizations and spinouts, securities offerings, and the formation of investment funds. Notable clients include Portland Seed Fund, GlobeSherpa, Giftango (sold to Incomm), Exterro, Sol Republic, Treehouse Island, Nouvola, Schoolhouse Electric, Black Rock Coffee Bar, and Ruby Receptionists. Jon speaks frequently on the subjects of startups, financings, and mergers & acquisitions. Jon teaches an Entrepreneurship seminar at Lewis & Clark Law School. Prior to his legal career, Jon worked for four years for Arthur Andersen & Co., an international public accounting firm, as a financial statement auditor where he earned his certified public accounting license in 1989.


Lance Termes is a patent attorney with Schwabe, Williamson & Wyatt.  Before recently relocating to Bend, Lance spent the prior ten years in the San Francisco Bay Area representing large pharmaceutical and local biotechnology companies.  Lance’s practice is largely focused on helping clients protect their innovations in the fields of biopharmaceuticals and biotechnology, with an emphasis in immunology and the treatment of autoimmune diseases and cancers.  Lance has more than 18 years of experience counseling clients on comprehensive global patent strategies, and acquiring patents on behalf of clients throughout the world.  Lance’s experience includes work as both an in-house attorney and outside counsel, which gives him a client-focused perspective on service and communication.

Becky Voorheis
is CEO and co-founder of Quickbeam, Inc.  a startup drug development company in Beaverton, Oregon which holds an exclusive license from OHSU to a family of novel VMAT-2 inhibiting compounds developed for the treatment of methamphetamine addiction. Becky has over 18 years of experience in strategic investments, mergers & acquisitions, in- and out-licensing, and business development in both high-tech and life sciences. Prior to Quickbeam, she was the VP of business development for Apexian Pharmaceuticals, a startup biotech with a portfolio of anti-cancer therapeutics out of Indianapolis, Indiana, where Becky helped the company raise multiple millions in investment capital. Before Apexian, she was VP of investments for a life sciences venture capital fund, group director of mergers & acquisitions at Cadence Design Systems, and senior manager of strategic investments for Intel Capital. Becky has a BA from Swarthmore College and an MBA from Duke University. She lives in Beaverton, Oregon with her husband, two children, and big, sleepy dog. 

Patti White is the Co-founder and CEO of Hemex Health.  Patti brings 22 years of experience in medical technology and has launched over 20 successful products, including many in emerging markets.    Her first start-up invented a low-cost patient monitor with sales of over $100M. Her experience spans cardiology, critical care, pain medicine, ophthalmology and behavioral health.   Prior to her start-up career, Patti ran marketing for Hewlett Packard’s $400M PC business and for HP’s Cardiology division. She has raised over $70M in grant, angel, venture and corporate funding. Patti holds an MBA from The Wharton School at the University of Pennsylvania and a BA in International Business from the University of Washington.